1. Home
  2. NX vs RCUS Comparison

NX vs RCUS Comparison

Compare NX & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NX
  • RCUS
  • Stock Information
  • Founded
  • NX 1927
  • RCUS 2015
  • Country
  • NX United States
  • RCUS United States
  • Employees
  • NX N/A
  • RCUS N/A
  • Industry
  • NX Metal Fabrications
  • RCUS Biotechnology: Pharmaceutical Preparations
  • Sector
  • NX Industrials
  • RCUS Health Care
  • Exchange
  • NX Nasdaq
  • RCUS Nasdaq
  • Market Cap
  • NX 824.7M
  • RCUS 906.4M
  • IPO Year
  • NX N/A
  • RCUS 2018
  • Fundamental
  • Price
  • NX $18.89
  • RCUS $9.98
  • Analyst Decision
  • NX Strong Buy
  • RCUS Buy
  • Analyst Count
  • NX 1
  • RCUS 10
  • Target Price
  • NX $38.00
  • RCUS $23.75
  • AVG Volume (30 Days)
  • NX 370.9K
  • RCUS 1.2M
  • Earning Date
  • NX 06-05-2025
  • RCUS 05-06-2025
  • Dividend Yield
  • NX 1.69%
  • RCUS N/A
  • EPS Growth
  • NX N/A
  • RCUS N/A
  • EPS
  • NX 0.39
  • RCUS N/A
  • Revenue
  • NX $1,625,028,000.00
  • RCUS $141,000,000.00
  • Revenue This Year
  • NX $48.92
  • RCUS N/A
  • Revenue Next Year
  • NX $3.10
  • RCUS $27.28
  • P/E Ratio
  • NX $48.26
  • RCUS N/A
  • Revenue Growth
  • NX 47.66
  • RCUS N/A
  • 52 Week Low
  • NX $15.30
  • RCUS $6.50
  • 52 Week High
  • NX $34.97
  • RCUS $18.98
  • Technical
  • Relative Strength Index (RSI)
  • NX 59.72
  • RCUS 62.57
  • Support Level
  • NX $16.09
  • RCUS $9.29
  • Resistance Level
  • NX $18.25
  • RCUS $10.68
  • Average True Range (ATR)
  • NX 0.77
  • RCUS 0.61
  • MACD
  • NX 0.04
  • RCUS 0.10
  • Stochastic Oscillator
  • NX 48.91
  • RCUS 69.57

About NX Quanex Building Products Corporation

Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its three operating segments are North American Fenestration being the key revenue driver, European Fenestration, and North American Cabinet Components. Geographically, it derives a majority of revenue from the United States.

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Share on Social Networks: